Literature DB >> 22740984

Cotreatment with dichloroacetate and omeprazole exhibits a synergistic antiproliferative effect on malignant tumors.

Tatsuaki Ishiguro1, Miyu Ishiguro, Ryumei Ishiguro, Sayuri Iwai.   

Abstract

It has been reported that treating cancer cells with dichloroacetate (DCA), an approved treatment for congenital lactic acidosis, reverses the Warburg effect and inhibits tumor growth). Furthermore, omeprazole (OMP) is a well-known agent that enhances the effects of anticancer drugs. The aim of this study was to find clinically-used drugs that enhance the effects of DCA. The combination of DCA and OMP exhibited a more potent antitumor activity than DCA alone in HT1080 fibrosarcoma cells and RKO colon cancer cells, while the drugs did not affect the proliferation of WI-38 human fibroblasts. The inhibitory effect of DCA combined with OMP was reversed with vitamin E and Z-VAD-FMK; therefore conventional caspase-dependent cell growth inhibition through superoxide production was suggested as the mechanism for inhibition. The combination of these drugs also had an effect on HT1080 fibrosarcoma cells inoculated into mice. Since OMP and DCA may be administered orally and have been used clinically for several years without major side effects, we believe that this combination therapy could be readily translated to treat malignant tumors.

Entities:  

Year:  2012        PMID: 22740984      PMCID: PMC3362455          DOI: 10.3892/ol.2012.552

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  19 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

Review 2.  Safety of the long-term use of proton pump inhibitors.

Authors:  Alan B R Thomson; Michel D Sauve; Narmin Kassam; Holly Kamitakahara
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

3.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.

Authors:  Sébastien Bonnet; Stephen L Archer; Joan Allalunis-Turner; Alois Haromy; Christian Beaulieu; Richard Thompson; Christopher T Lee; Gary D Lopaschuk; Lakshmi Puttagunta; Sandra Bonnet; Gwyneth Harry; Kyoko Hashimoto; Christopher J Porter; Miguel A Andrade; Bernard Thebaud; Evangelos D Michelakis
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

Review 4.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-08-05       Impact factor: 2.953

Review 5.  Pharmacokinetics, metabolism and toxicology of dichloroacetate.

Authors:  P W Stacpoole; G N Henderson; Z Yan; R Cornett; M O James
Journal:  Drug Metab Rev       Date:  1998-08       Impact factor: 4.518

Review 6.  The pharmacology of dichloroacetate.

Authors:  P W Stacpoole
Journal:  Metabolism       Date:  1989-11       Impact factor: 8.694

7.  Age-dependent kinetics and metabolism of dichloroacetate: possible relevance to toxicity.

Authors:  Albert L Shroads; Xu Guo; Vaishali Dixit; Hui-Ping Liu; Margaret O James; Peter W Stacpoole
Journal:  J Pharmacol Exp Ther       Date:  2007-12-20       Impact factor: 4.030

8.  Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.

Authors:  Francesca Luciani; Massimo Spada; Angelo De Milito; Agnese Molinari; Licia Rivoltini; Annalisa Montinaro; Manuela Marra; Luana Lugini; Mariantonia Logozzi; Francesco Lozupone; Cristina Federici; Elisabetta Iessi; Giorgio Parmiani; Giuseppe Arancia; Filippo Belardelli; Stefano Fais
Journal:  J Natl Cancer Inst       Date:  2004-11-17       Impact factor: 13.506

9.  Development of a less toxic dichloroacetate analogue by docking and descriptor analysis.

Authors:  Kannan Subramanian; Anand S Ramaian
Journal:  Bioinformation       Date:  2010-07-06

Review 10.  Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer.

Authors:  E D Michelakis; L Webster; J R Mackey
Journal:  Br J Cancer       Date:  2008-09-02       Impact factor: 7.640

View more
  20 in total

1.  Metabolic-targeted Combination Therapy With Dichloroacetate and Metformin Suppresses Glioblastoma Cell Line Growth In Vitro and In Vivo.

Authors:  Laura Korsakova; Jan Aleksander Krasko; Edgaras Stankevicius
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

2.  Dichloroacetate induced intracellular acidification in glioblastoma: in vivo detection using AACID-CEST MRI at 9.4 Tesla.

Authors:  Mohammed Albatany; Alex Li; Susan Meakin; Robert Bartha
Journal:  J Neurooncol       Date:  2017-11-16       Impact factor: 4.130

3.  Distinct roles of histamine H1- and H2-receptor signaling pathways in inflammation-associated colonic tumorigenesis.

Authors:  Zhongcheng Shi; Robert S Fultz; Melinda A Engevik; Chunxu Gao; Anne Hall; Angela Major; Yuko Mori-Akiyama; James Versalovic
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-11-21       Impact factor: 4.052

4.  Brain tumor acidification using drugs simultaneously targeting multiple pH regulatory mechanisms.

Authors:  Mohammed Albatany; Valeriy G Ostapchenko; Susan Meakin; Robert Bartha
Journal:  J Neurooncol       Date:  2019-08-07       Impact factor: 4.130

5.  Synergistic Anti-tumor Effect of Dichloroacetate and Ivermectin.

Authors:  Tatsuaki Ishiguro; Ryumei H Ishiguro; Miyu Ishiguro; Atsushi Toki; Hiroshi Terunuma
Journal:  Cureus       Date:  2022-02-03

Review 6.  Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance.

Authors:  Ethan B Butler; Yuhua Zhao; Cristina Muñoz-Pinedo; Jianrong Lu; Ming Tan
Journal:  Cancer Res       Date:  2013-04-22       Impact factor: 12.701

7.  AG311, a small molecule inhibitor of complex I and hypoxia-induced HIF-1α stabilization.

Authors:  Anja Bastian; Satoshi Matsuzaki; Kenneth M Humphries; Gavin A Pharaoh; Arpit Doshi; Nilesh Zaware; Aleem Gangjee; Michael A Ihnat
Journal:  Cancer Lett       Date:  2016-12-08       Impact factor: 8.679

8.  Siomycin A induces reactive oxygen species-mediated cytotoxicity in ovarian cancer cells.

Authors:  Xiulan Shao; Fengying Zhang; Xiang Gao; Fengying Xu
Journal:  Oncol Lett       Date:  2021-03-31       Impact factor: 2.967

Review 9.  Targeting cellular metabolism to improve cancer therapeutics.

Authors:  Y Zhao; E B Butler; M Tan
Journal:  Cell Death Dis       Date:  2013-03-07       Impact factor: 8.469

10.  Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib.

Authors:  W Y Sanchez; S L McGee; T Connor; B Mottram; A Wilkinson; J P Whitehead; S Vuckovic; L Catley
Journal:  Br J Cancer       Date:  2013-03-26       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.